How much upside does Macquarie predict for Sonic Healthcare shares?

Macquarie has released its latest forecast for Sonic Healthcare shares.

Key points
  • Sonic Healthcare shares rose 7.8% over the week, outperforming the ASX 200 Index, but remain down 16.6% year-on-year.
  • The company's AGM on Thursday reaffirmed its FY 2026 EBITDA guidance, projecting up to a 12.7% increase from FY 2025 if targets are met.
  • Macquarie noted potential synergy benefits from recent acquisition alongside margin and regulatory challenges.

Sonic Healthcare Ltd (ASX: SHL) shares were among the best performers on the S&P/ASX 200 Index (ASX: XJO) this past week.

Shares in the ASX 200 global pathology provider closed up 0.6% on Friday, trading for $22.98 apiece. This put the share price up 7.8% in a week that saw the benchmark Aussie index close down 2.5%.

Longer-term, Sonic Healthcare shares remain down 16.6% over 12 months, trailing the 1.1% one-year gains delivered by the ASX 200.

Though that's not including the $1.07 a share in partly franked dividends the healthcare stock has paid out over this time. At Friday's closing price, Sonic Healthcare stock trades on a partly franked trailing dividend yield of 4.7%.

Which brings us back to our headline question.

Following on this past week's gains, what target does Macquarie Group Ltd (ASX: MQG) have on the stock?

Research, collaboration and doctors working digital tablet, analysis and discussion of innovation cancer treatment. Healthcare, teamwork and planning by experts sharing idea and strategy for surgery.

Image source: Getty Images

What's the outlook for Sonic Healthcare shares?

Much of the ASX 200 healthcare stock's outperformance this past week came on the heels of the company's annual general meeting (AGM) on Thursday, where management also provided an FY 2026 trading update through to October.

Sonic Healthcare shares closed up 6.3% on the day, with the company reaffirming that it's on track to meet its FY 2026 earnings before interest, taxes, depreciation and amortisation (EBITDA) guidance. Management is forecasting full-year EBITDA will come in between $1.87 billion and $1.95 billion (on a constant currency basis).

If Sonic Healthcare achieves the higher end of that range, that would represent a 12.7% EBITDA increase from FY 2025.

Taking a closer look at Sonic's FY 2026 guidance, Macquarie noted:

SHL expects a 2H26 weighting to their EBITDA at ~54-55%, which is "consistent with historical weighting due to seasonality". We expect pathology margin dilution in FY26E vs FY25 due to SHL's recent margin-dilutive acquisitions (LADR, Swiss businesses, UK contract).

The broker added:

SHL expects the US Protecting Access to Medicare Act (PAMA) to be deferred or cancelled, with guidance excluding the potential ~A$15m impact of fee reductions in US from January 2026 (in line with previous guidance commentary).

Following Thursday's update, Macquarie maintained a neutral rating on Sonic Healthcare shares.

Still, the broker has a 12-month price target of $25.20 a share for the ASX 200 healthcare stock. That represents a potential upside of almost 10% from Friday's closing price. And it doesn't include those two upcoming dividends.

Macquarie concluded:

While acknowledging potential synergy benefits from recent acquisitions, we note margin headwinds and elevated leverage in the near term. Further, risks remain around PAMA, Fair Work decision and full impacts from fee cuts.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool Australia has recommended Sonic Healthcare. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

An unhappy man in a suit sits at his desk with his arms crossed staring at his laptop screen as the PointsBet share price falls
Broker Notes

BHP, Westpac, CSL shares: Buy, sell, or hold?

One of these ASX shares is tipped to fall 13%.

Read more »

Woman tying up her shoelaces before a run.
Broker Notes

Buy, hold, sell: Coles, Wesfarmers, CSL shares

It's a new week and we've got new ratings from the experts.

Read more »

a man in a business suite throws his arms open wide above his head and raises his face with his mouth open in celebration in front of a background of an illuminated board tracking stock market movements.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

Two male ASX investors and executives wearing dark coloured suits sit at a table holding their mobile phones discussing the highest trading ASX 200 shares today
Broker Notes

Buy, hold, sell: Resmed, Goodman Group, CBA shares

We review three fresh buy, hold, and sell calls from John Athanasiou at Red Leaf Securities.

Read more »

colleagues on a lunch break looking at iPhone
Broker Notes

Top brokers name 3 ASX shares to buy now

Here's what brokers are recommending as buys this week.

Read more »

Woman with her fingers crossed and eyes shut.
Broker Notes

7 ASX 200 shares in the buy zone as optimism returns to the market: experts

Brokers reaffirmed their buy calls on Liontown, Rio Tinto, Xero, and others this week.

Read more »

ASX shares broker ratings represented by three different coloured buttons.
Broker Notes

6 ASX shares upgraded and downgraded by the experts this week

Brokers have changed their ratings and 12-month price targets on Qantas, Codan, and others. 

Read more »

A woman sits in a cafe wearing a polka dotted shirt and holding a latte in one hand while reading something on a laptop that is sitting on the table in front of her
Broker Notes

Buy, hold, sell: CSL, NextDC, PLS shares

Mark Elzayed from Vestra Capital explains his ratings on three ASX 200 shares.

Read more »